Novo Nordisk testing found over 24% impurities in some compounded samples, underscoring that compounded medications don't undergo the same level of purity validation as FDA-approved products
Lilly's TRIUMPH clinical program includes multiple Phase III trials evaluating retatrutide across different patient populations and endpoints: Seven additional Phase III readouts are expected throughout 2026, covering populations with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities Cardiovascular outcomes data the gold standard for demonstrating that weight loss translates into reduced heart attacks, strokes, and cardiovascular death will be critical for retatrutide's regulatory and commercial positioning Head-to-head trials comparing retatrutide directly to existing therapies may provide definitive comparative efficacy data The Drug vs
Corrected and uncorrected ETC activity is shown in Figures 5a and b, respectively, and demonstrate a partial defect in complexes I/III and I/III rotenone sensitive (RS)
For differentiating pretreatment from posttreatment subjects, a set of ten acyl-carnitines, including C2, C4, C4OH (C3DC), C10:1, C14:1, C14:1OH, C14:2, C16:1OH, C16:2, and C18:1, was used to build the ROC curve with the AUC = 0.851 (95% CI: 0.8100.892), which indicated a high accuracy in predicting different groups
Treatment typically follows a stepwise approach, allowing the body to adjust over time
